Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD7 CAR-T for R/R Mature T-Cell Lymphomas
NCT06925464Phase 2Recruiting
- Sponsor
- Beijing Gaobo Hospital
- Start
- Apr 2025
- Primary completion
- Apr 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CD7 CAR-T cells injection in T-cell non-Hodgkin lymphoma, sponsored by Beijing Gaobo Hospital. Primary endpoints: Dose-limiting toxicity at 21 days and Adverse events at 21 days. Started Apr 2025; status: recruiting.
02
Drugs
CD7 CAR-T cells injection
03
Conditions
T-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT06925464.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06925464.